AU2001292529A1 - Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight - Google Patents

Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight

Info

Publication number
AU2001292529A1
AU2001292529A1 AU2001292529A AU9252901A AU2001292529A1 AU 2001292529 A1 AU2001292529 A1 AU 2001292529A1 AU 2001292529 A AU2001292529 A AU 2001292529A AU 9252901 A AU9252901 A AU 9252901A AU 2001292529 A1 AU2001292529 A1 AU 2001292529A1
Authority
AU
Australia
Prior art keywords
starch
molecular weight
active substance
vaccine composition
immunologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001292529A
Inventor
Nils Ove Gustafsson
Monica Jonsson
Timo Laakso
Karin Larsson
Mats Reslow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Bioglan AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0003615A external-priority patent/SE517421C2/en
Application filed by Bioglan AB filed Critical Bioglan AB
Publication of AU2001292529A1 publication Critical patent/AU2001292529A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/20—After-treatment of capsule walls, e.g. hardening
    • B01J13/22—Coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001292529A 2000-10-06 2001-10-05 Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight Abandoned AU2001292529A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0003615A SE517421C2 (en) 2000-10-06 2000-10-06 New production of microparticles involves use of aqueous solution of purified amylopectin-based starch of reduced molecular weight
SE0003615 2000-10-06
US26045501P 2001-01-08 2001-01-08
US60260455 2001-01-08
PCT/SE2001/002169 WO2002028371A1 (en) 2000-10-06 2001-10-05 Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight

Publications (1)

Publication Number Publication Date
AU2001292529A1 true AU2001292529A1 (en) 2002-04-15

Family

ID=26655255

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2001294458A Ceased AU2001294458B2 (en) 2000-10-06 2001-10-05 Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight
AU2001292529A Abandoned AU2001292529A1 (en) 2000-10-06 2001-10-05 Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight
AU9445801A Pending AU9445801A (en) 2000-10-06 2001-10-05 Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001294458A Ceased AU2001294458B2 (en) 2000-10-06 2001-10-05 Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU9445801A Pending AU9445801A (en) 2000-10-06 2001-10-05 Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight

Country Status (10)

Country Link
US (1) US20020098203A1 (en)
EP (2) EP1322291A1 (en)
JP (2) JP2004510724A (en)
KR (1) KR20030051687A (en)
CN (1) CN100352427C (en)
AU (3) AU2001294458B2 (en)
CA (2) CA2424936A1 (en)
HK (1) HK1061981A1 (en)
HU (1) HUP0302622A3 (en)
WO (2) WO2002028371A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2844514B1 (en) * 2002-09-16 2007-10-19 Neovacs STABLE IMMUNOGENIC PRODUCT COMPRISING ANTIGENIC HETEROCOMPLEXES, COMPOSITIONS CONTAINING SAME, AND PREPARATION METHOD
JP2006521287A (en) * 2002-12-20 2006-09-21 エスティ．ジェイムス アソシエイト エルエルシー／フェイバー リサーチ シリーズ High pressure compression for pharmaceutical formulations
US7060299B2 (en) 2002-12-31 2006-06-13 Battelle Memorial Institute Biodegradable microparticles that stabilize and control the release of proteins
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
CN103393601A (en) * 2004-05-12 2013-11-20 巴克斯特国际公司 Microspheres comprising protein and showing injectability at high concentration of protein
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
EP1726299A3 (en) 2005-05-27 2007-04-18 StratoSphere Pharma AB Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
US8017152B2 (en) 2005-05-27 2011-09-13 Stratosphere Pharma Ab Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
US20060269576A1 (en) * 2005-05-27 2006-11-30 Curalogic, A/S Non-injection immunotherapy
EP1931311A4 (en) 2005-08-29 2010-12-08 Tuo Jin Polysaccharide microparticles containing biological agents: there preparation and applications
EP1948695B1 (en) * 2005-10-25 2012-12-19 Artificial Cell Technologies, Inc. Immunogenic compositions and methods of use
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
KR100956415B1 (en) * 2008-06-13 2010-05-06 이진호 Manufacturing method of polymeric microspheres
EP2349224B1 (en) 2008-10-10 2017-05-10 Probelte Pharma, S.A. Orally administrable immunostimulant product for aquaculture
JP5361407B2 (en) * 2009-01-21 2013-12-04 株式会社東芝 X-ray diagnostic imaging apparatus, image processing apparatus, and control program
WO2012054807A2 (en) * 2010-10-22 2012-04-26 President And Fellows Of Harvard College Vaccines comprising bisphosphonate and methods of use thereof
US20150125498A1 (en) * 2010-12-15 2015-05-07 Speximo Ab New particle stabilized emulsions and foams
CN104394846B (en) 2012-05-03 2018-10-19 爱尔兰詹森科学公司 Polyinosinic acid-polycytidylicacid for treating the infection of the upper respiratory tract（Poly- (I:C)）Preparation
US11470811B2 (en) * 2012-09-11 2022-10-18 Pioneer Pet Products, Llc Extruded granular absorbent
RU2015144689A (en) 2013-03-21 2017-04-25 ЮПРАКСИЯ ФАРМАСЬЮТИКАЛЗ ЮЭсЭй ЭлЭлСи COMPOSITION FOR INJECTIONS WITH SLOW DELIVERY AND METHOD OF ITS APPLICATION FOR TREATMENT OF INFLAMMATION IN JOINTS AND RELATED TO SUCH INFLAMMATIONS OF PAIN
EP2898894A1 (en) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-micro particles for intradermal delivery
AU2016313969B2 (en) * 2015-06-19 2021-12-23 Sillajen, Inc. Compositions and methods for viral embolization
CN108289857A (en) 2015-10-27 2018-07-17 优普顺药物公司 The extended release preparation of local anesthetic
CN106902716B (en) * 2017-02-27 2020-02-14 广西科学院 Preparation method of small-particle-size starch microspheres

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713249A (en) * 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
JPH0699529B2 (en) * 1985-06-28 1994-12-07 モンサント化成株式会社 Method for producing vinyl cyanide compound / aromatic vinyl compound copolymer resin
CA2136307A1 (en) * 1992-04-20 1993-10-28 Bruce K. Redding, Jr. Method and apparatus for the modification of starch and other polymers
AU1702395A (en) * 1994-02-17 1995-09-04 Pankaj Modi Drugs, vaccines and hormones in polylactide coated microspheres
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5959102A (en) * 1997-06-30 1999-09-28 Rutgers University Starch purification by thermally tolerant broad pH range proteolytic enzymes
NL1006444C2 (en) * 1997-07-01 1999-01-05 Inst Voor Agrotech Onderzoek Encapsulation of active substances.
SE512663C2 (en) * 1997-10-23 2000-04-17 Biogram Ab Active substance encapsulation process in a biodegradable polymer

Also Published As

Publication number Publication date
EP1322291A1 (en) 2003-07-02
KR20030051687A (en) 2003-06-25
WO2002028371A1 (en) 2002-04-11
AU9445801A (en) 2002-04-15
CN100352427C (en) 2007-12-05
CA2424892A1 (en) 2002-04-11
HUP0302622A2 (en) 2003-11-28
CN1468093A (en) 2004-01-14
JP2004510724A (en) 2004-04-08
AU2001294458B2 (en) 2004-03-11
HUP0302622A3 (en) 2006-07-28
CA2424936A1 (en) 2002-04-11
HK1061981A1 (en) 2004-10-15
WO2002028370A1 (en) 2002-04-11
JP2004510723A (en) 2004-04-08
EP1322290A1 (en) 2003-07-02
US20020098203A1 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
AU2001292529A1 (en) Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight
AU2002225681A1 (en) Yeast-dentritic cell vaccines and uses thereof
AU2003235707A1 (en) Immunogenic preparations and vaccines on the basis of mrna
AU1219401A (en) Methods and devices for improving cardiac function in hearts
HK1083190A1 (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
AU1790301A (en) In ovo delivery of an immunogen containing implant
AU2001282267A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
AU4661900A (en) Noscapine derivatives as adjuvant compositions and methods of use thereof
AU2001241918A1 (en) Methods of enhancing activity of vaccines and vaccine compositions
EE04490B1 (en) The compound, its method of preparation and its use in medicine
AU2868200A (en) Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
AU1164601A (en) Therapeutic use and formulation
HUP0201486A2 (en) Arylmalonic acid dinitrile derivatives, preparation and use thereof
IL206604A (en) Transmembrane protein, 24p4c12, expressed in prostate cancer, immunogenic compositions comprising them and uses thereof
AU5137800A (en) Cd4-independent hiv envelope proteins as vaccines and therapeutics
AU5577201A (en) Immunogenic pneumococcal protein and vaccine compositions thereof
AU2001271976A1 (en) Microspheres and adjuvants for dna vaccine delivery
HUP0202864A3 (en) Endoparasiticidal gel composition preparation and use thereof
IS6381A (en) Novelty in the use of antibodies in vaccines
DE60012415D1 (en) Virtual mailbox
AUPR218000A0 (en) Polymer gels and their preparation
HUP0201810A2 (en) Sootepenseone and its derivatives, their preparation and use as medicament
AU2001295672A1 (en) Vaccine composition and stabilisation method
DE60022360D1 (en) Crosslinked foam of Ethylene-vinyl acetate and Acid copolymer
IL148446A0 (en) Iren protein, its preparation and use